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Abstract: 
Objective: Assess the prognostic impact of Cardiovascular Magnetic Resonance (CMR) and 
conventional risk factors in patients with Myocardial infarction with non-obstructed coronaries 
(MINOCA). 
Background: MINOCA represents a diagnostic dilemma and the prognostic markers have not 
been clarified. 
Methods: 388 consecutive MINOCA patients undergoing CMR assessment were identified 
retrospectively from registry database and prospectively followed up for a primary clinical 
endpoint of all-cause mortality. 1.5T CMR was performed using a comprehensive protocol 
(cines, T2-weighted, and late gadolinium enhancement sequences). Patients were grouped into 4 
categories based on their CMR findings: myocardial infarction (MI) (embolic/spontaneous 
recanalization), myocarditis, cardiomyopathy and normal CMR.  
Results: CMR(performed at a median of 37days from presentation) was able to identify the cause 
for the troponin rise in 74% of the patients (25% myocarditis, 25% MI and 25% 
cardiomyopathy), whilst a normal CMR was identified in 26%. Over a median follow-up of 
1262days(3.5years), 5.7% patients died. Cardiomyopathy group had the worst prognosis 
(mortality 15%, log rank 19.9 p<0.001), MI had 4% mortality, and 2% in both myocarditis and 
normal CMR. In a multivariable cox regression model (including clinical and CMR parameters), 
CMR diagnosis of cardiomyopathy and ST-segment elevation on presentation ECG remained the 
only 2 significant predictors of mortality. Using presentation with ECG ST-elevation and CMR 
diagnosis of cardiomyopathy as risk markers, the mortality risk rates were 2%, 11% and 21% for 
presence of 0, 1 and 2 factor respectively(p<0.0001).  
Conclusion: In a large cohort of MINOCA, CMR(median 37days from presentation)  identified a 
final diagnosis in 74% of patients. Cardiomyopathy had the highest mortality, followed by MI. 
The strongest predictors of mortality were a CMR diagnosis of cardiomyopathy and ST-elevation 
on presentation ECG.  
 
Keywords: MINOCA, Myocarditis, ACS unobstructed coronaries, CMR, Takotsubo 
cardiomyopathy, myocardial infarction  
 
Abbreviations: 
ACS – Acute coronary syndrome 
CMR – Cardiac magnetic resonance 
LGE – Late gadolinium enhancement  
MINOCA – Myocardial infarction with non-obstructed coronary 
NSTE-ACS – Non ST-segment elevation - Acute coronary syndrome 
RWMA – Regional wall motion abnormality 
STEMI – ST-segment elevation myocardial infarction 
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Introduction 
Acute coronary syndrome (ACS) is one of the leading causes of mortality and morbidity 
worldwide.(1) Definite diagnosis of ACS is crucial for ensuring appropriate patient management. 
As per the international guidelines, patients presenting with ST-segment elevation myocardial 
infarction (STEMI) or non-ST-segment elevation-acute coronary syndrome (NSTE-ACS) 
proceed to immediate or inpatient coronary angiography, respectively, with the aim to identify 
and treat a culprit coronary artery occlusion or stenosis.(2,3) However, in 1-14% of these 
patients no significant coronary obstruction is identified, thus being classified as MINOCA 
(Myocardial infarction with non-obstructive coronary arteries).(3) MINOCA represents a 
diagnostic dilemma, with subsequent uncertain clinical management. A recent registry study has 
shown beneficial effects of treatment with statins and angiotensin-converting enzyme 
inhibitors/angiotensin receptor blockers on outcome in patients with MINOCA.(4) 
The underlying pathophysiological mechanisms occurring in MINOCA are complex and 
multifactorial. (5) Patients with MINOCA are thought to have a better prognosis, and 
consequently do not receive appropriate secondary prevention medications.(6) However, recent 
studies suggest that all-cause mortality may be as high as 4.7% at 12 months.(7,8) The latest 
ESC guidelines on the management of STEMI and the recent ESC/ACC/AHA/WHF Fourth 
universal definition of myocardial infarction has included MINOCA suggesting a potential role 
for cardiovascular magnetic resonance (CMR) in this cohort.(3)(9) 
Confirmation or exclusion of myocardial infarction (MI) by CMR facilitates tailoring of medical 
therapy, ensuring appropriate long-term secondary prevention and modification of risk, and also 
minimizing exposure to anti-platelet therapy and the associated bleeding risks for those with a 
non-coronary aetiology for the MINOCA presentation.(10). Few previous studies have shown 
that CMR can identify the underlying diagnosis, most commonly: acute/chronic myocarditis, 
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acute MI with spontaneous recanalization/embolus, stress cardiomyopathy (Takotsubo) or other 
cardiomyopathies.(11–17) Only in a small proportion of cases, no abnormality is identified by 
CMR. The variable proportion of normal cases in the different studies may be due to the time 
delay between the acute presentation and CMR, (18) suggesting that the time between acute 
presentation and CMR can play a role in identifying the early reversible abnormalities that may 
resolve when patients are scanned later. Recent studies have demonstrated the prognosis in the 
individual diagnostic categories like myocarditis and Takotsubo cardiomyopathy. (19–21) 
However, there is no evidence in the literature on the prognostic significance of the CMR 
findings and conventional risk factors in MINOCA. The only study which looked at mid-term 
mortality was by Mittal et al. (22) However, they looked at patients presenting via the primary 
percutaneous coronary angiography pathway with non-obstructed coronaries. 60% of the study 
population had normal troponin thereby not strictly meeting MINOCA criteria. Our study aims to 
assess the prognostic impact of CMR and conventional risk factors in patients with MINOCA. 
Methods  
Study population 
In this longitudinal observational study, consecutive patients presenting with MINOCA (chest 
pain, elevated troponin and non-obstructed coronary arteries) as per the new ESC STEMI 
Guideline(3) and undergoing CMR were identified retrospectively and  followed up 
prospectively (Figure 1).  We excluded patients admitted with suspected heart failure or 
arrhythmic events at presentation. The study was performed at a large cardiothoracic tertiary 
centre in the South-West of England; data were collected on consecutive patients scanned from 
September 2011 to December 2015. Patients were identified either presenting with STEMI or 
NSTEMI.  Non-obstructed coronaries were defined as: TIMI III flow; <50% stenosis in any 
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coronary artery.(3) Troponin T level <14ng/L was considered normal. The typical rise and/or fall 
of Troponin T was used for the diagnosis of acute MI. (9)‘False positive’ troponin possibilities: a 
single troponin elevation (<5x upper limit of normal), which was not repeated during the 
admission or if a single elevated troponin was followed by a second normal troponin level within 
24 h were excluded from study. (2) 
The study was reviewed and approved by the local Institutional Review Board.  
CMR protocol  
CMR was performed at 1.5T (Magnetom Avanto, Siemens Healthineers, Enlargen, Germany). A 
comprehensive CMR protocol was carried out including cine, T2-weighted (myocardial 
oedema), early and late gadolinium enhancement imaging. (23) In particular, cine images were 
performed using a steady-state free-precession sequence acquired in three long axis planes and a 
stack of short axis images covering the left ventricle (LV) and T2-weighted (T2-STIR) sequence 
images were acquired in the same short-axis and long-axis planes as the cine images with 
standard parameters, as previously described.(24,25) Intravenous gadolinium-chelate contrast 
agent (gadobutrol) was administered at a dose of 0.1 mmol kg–1 of body weight. Images were 
acquired 2-3min after contrast injection (early gadolinium), whilst late gadolinium enhancement 
(LGE) images were acquired 15-20minutes after contrast injection using a standard inversion 
recovery segmented gradient echo sequence, as previously described. (24,25)  
CMR analysis  
All CMR studies were analysed and reported by a consultant with >15 years of CMR experience 
and with ESC CMR level 3 certification (CBD).  Diffuse and focal myocardial oedema was 
analysed using both the early gadolinium and the T2-STIR images. Myocardial oedema was 
considered present when the ratio of signal intensity between the myocardium and the mean 
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signal intensity of the skeletal muscle was >2 on T2-STIR images, according to the Lake Louise 
criteria. (26) Early gadolinium enhancement ratio used for assessment of hyperaemia was 
evaluated as previously described. (26) Patients were grouped into 4 categories based on their 
CMR characteristics: myocardial infarction (MI) (embolic/spontaneous recanalization), 
myocarditis, cardiomyopathy and normal CMR. The latter corresponded to a structurally normal 
heart, defined as no regional wall motion abnormality (RWMA) (except for dyssynchrony 
secondary to bundle branch block), no myocardial oedema, and no myocardial LGE (scarring) 
(except non-specific LGE in LV/RV insertion points). Myocarditis was diagnosed based on 
fulfilling two out of three Lake Louise Criteria: T2- STIR sequences detecting myocardial 
oedema; early gadolinium sequences detecting hyperaemia; epicardial or mid-myocardial LGE, 
as previously described (26). MI was diagnosed based on territorial subendocardial and/or 
transmural LGE. Takotsubo cardiomyopathy was diagnosed based on the T2- STIR images 
detecting myocardial oedema and regional wall motion in the mid-cavity or apical distribution 
with no myocardial LGE, all in accordance with the modified Mayo Clinic criteria.(27)  Dilated 
cardiomyopathy, hypertrophic cardiomyopathy and cardiac amyloidosis were detected based on 
specific tissue characterization characteristics and were all grouped under cardiomyopathy 
together with Takotsubo cardiomyopathy.(15) The extent of LGE and myocardial oedema was 
quantified by calculating the number of segments involved.(20) 
Study primary end-point 
The end-point of the present study was all-cause mortality.  
Patient related data were collected directly from medical records. Follow up was performed 
centrally by analysing the mortality data obtained from the NHS summary care records. Data 
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was collected and interpreted by one of the primary investigators (AGD, AB, EDG, GB) in all 
cases.  
Statistical analysis  
Baseline patient characteristics, conventional risk markers and CMR findings are described 
according to the diagnostic groups. Data for continuous variables are presented in mean ± 
standard deviation or medians as appropriate. Categorical variables are presented as frequencies 
and percentages. Normally distributed continuous variables were compared using one-way 
analysis of variance with (ANOVA) with Bonferroni correction for multiple comparisons. 
Continuous variables that were not normally distributed were compared by Kruskal–Wallis tests. 
In univariate analyses the association of time variables to mortality was assessed using Kaplan–
Meier curves and the log-rank test. Univariable and multivariable associations of risk covariates 
with mortality were assessed using Cox proportional hazard regression analyses. Only variables 
with a p value<0.05 in univariable analyses were used in multivariable model. SPSS Version 23 
(IBM Corp, Armonk, NY) was used for statistical analysis. Probability values were two-sided, 
and values of p<0.05 were considered significant. Due to paucity of mortality data on the 
MINOCA subgroups post-hoc power calculation was performed based on the study findings. 
Results 
11,757 patients underwent emergency or urgent coronary angiography during the recruitment 
period, out of which 410 patients with suspected MINOCA underwent CMR assessment. 2% 
(n=8) were excluded due to incomplete protocol and 3%(n=14) due to coronary artery disease 
which were deemed >50% stenosis thereby leaving a study sample size of 388. CMR was able to 
identify a cause for the troponin rise in 74% of cases. Clinical characteristics of the overall 
population (n=388) and for separate patients’ groups based on the CMR diagnosis are 
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summarized in Table 1. There was a low prevalence of cardiovascular risk factors (hypertension, 
diabetes, hyperlipidaemia, smoking and family history), with no difference across the groups. 
The median time delay between acute presentation and CMR was 37 days. 37% of our patients 
underwent the scan within 2 weeks from presentation. In a median follow up of 
1262days(3.5years), the overall all-cause mortality was 5.7%. 
Conventional risk factors  
Age: The mean age of the total population was 56±17years.  
Kaplan-Meier curves were drawn showing the risk of mortality according to the different age 
categories (<40years, 40-59years, 60-79years and >79years). There was a strong association 
between increasing age and mortality (Log rank 23.2, p<0.001) Figure 2a 
Gender: 48% of the total cohort was female. 98% of the patients diagnosed with Takotsubo 
cardiomyopathy were female. There was no significant association between gender and mortality 
in the overall cohort (log rank 2.5, p=0.1). 
ECG at presentation (STEMI or NSTE-ACS): 19% of our study population presented with 
ST-segment elevation on the 12-lead ECG.  
Kaplan-Meier curves were drawn showing the risk of mortality according to the ECG 
presentation as ST-elevation or no ST-elevation. There was a strong association between ECG 
presentation as ST-elevation and mortality (log rank 7.4, p=0.007). Figure 3 
CMR characteristics and diagnosis 
The CMR characteristics are described according to the diagnosis groups. Table 2 
MI was the most prevalent diagnosis (25%, 97/388 patients), followed by myocarditis (25%, 
96/388) and cardiomyopathy 25%, whilst 26% had a structurally normal heart and were grouped 
into the ‘normal CMR’ category.  
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LV volumes: In the overall cohort the mean indexed end-diastolic volume (iEDV) was 81ml/m2. 
On Bonferroni correction the iEDV in the cardiomyopathy was significantly higher than MI and 
normal CMR category. 
LV ejection fraction: The mean LV ejection fraction for the whole cohort was 61%. On 
Bonferroni correction the LVEF in the cardiomyopathy was significantly lower than MI, 
myocarditis and normal CMR category. In addition, the LVEF in the myocarditis was 
significantly lower than normal CMR category.  
Regional wall motion abnormalities: Overall 39% of patients had RWMA. The normal CMR 
category had RWMA secondary to bundle branch block on ECG. 
Myocardial oedema: The overall prevalence of focal myocardial oedema was 34% based on T2 
STIR and/ or early gadolinium enhancement. Focal myocardial oedema was absent in patients 
with normal CMR. Additional analysis of the normal CMR cohort revealed no evidence of 
diffuse myocardial injury in any of the patients.  
Late Gadolinium Enhancement: LGE was present in 58% of the entire cohort.  
6% of patients with normal CMR had evidence of LGE only in the LV/RV insertion points, 
currently considered a non-specific finding.  
Cardiomyopathy subgroup analysis 
In the cardiomyopathy group, 43% had Takotsubo cardiomyopathy, 29% dilated cardiomyopathy 
and 18% hypertrophic cardiomyopathy. The remaining comprised of infiltrative cardiomyopathy 
(amyloidosis)(n=4), hypertensive heart disease(n=4) and valvular heart disease(n=2) and were 
grouped as ‘other’. There was no statistically significant difference in the mean age and 
presentation as STEMI, however there was a significant difference in the gender among the 
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different cardiomyopathy subgroups. There was a significant difference in the CMR parameters 
among the different cardiomyopathy subgroups. Table 3 
Treatment prior to CMR 
The use of aspirin, other antiplatelet, ACE-Inhibitor/angiotensin receptor blocker, beta-blocker 
and statin use in the overall cohort was 93%, 61%, 66%, 65% and 57% respectively. There was 
no significant difference in the use of medications among the different diagnostic categories. 
Table 4. 
Prognosis in different CMR categories 
In a median follow up of 1262 days (3.5years), the overall all-cause mortality was 5.7% with 
worst prognosis identified in the cardiomyopathy group (15% mortality). The mortality rate in 
the different groups was: cardiomyopathy 15%, MI group 4%, myocarditis group 2%, and the 
normal group 2% (p=0.001). 
Kaplan-Meier curves were drawn showing the risk of mortality according to the different CMR 
diagnosis, showing a strong association between CMR categories and mortality (log rank 19.9, 
p<0.001). Figure 4a 
An additional Kaplan-Meier curve was drawn for Takotsubo cardiomyopathy, showing a 
significantly higher mortality in Takotsubo group compared to any other diagnosis (log rank 7.3, 
p=0.011). Figure 4b 
Predictors of all cause mortality 
Age, presentation with ST-elevation on ECG, iEDV, log troponin, LV ejection fraction and 
CMR diagnosis of cardiomyopathy were significant univariable predictors of mortality (p<0.05 
considered significant for univariate analysis). In a multivariable model only CMR diagnosis of 
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cardiomyopathy (hazard ratio 3.0, 95% CI 1.08-8.37, p=0.034) and ECG presentation with ST-
elevation (hazard ratio 3.1, 95% CI 1.27-7.68, p=0.013) remained significant. Table 5.  
Mortality risk markers (ECG presentation with ST-elevation + CMR diagnosis)   
A risk assessment tool for predicting mortality was constructed on the basis of the 2 variables: 
CMR diagnosis of cardiomyopathy and ECG presentation with ST-elevation. A first group was 
defined as 242 patients with any other CMR diagnosis except cardiomyopathy and presentation 
as NSTE-ACS. A second group consisted of 122 patients with only one of the factors altered i.e. 
either a CMR diagnosis of cardiomyopathy or ECG presentation with ST-elevation. Finally, the 
third group included 24 patients with CMR diagnosis of cardiomyopathy and ECG presentation 
with ST-elevation. The mortality rates in these 3 groups were (4/242) 1.6%, (13/122) 10.6%, and 
(5/24) 20.8%. respectively. Kaplan-Meier curves were drawn showing the risk of mortality in 
these 3 groups, showing a strong association between number of risk marker and mortality (log 
rank 23.6, p < 0.001). Figure 5. 
Post-hoc power calculation 
Using the mortality of 15% in the cardiomyopathy group vs 3% for the rest of the cohort with an 
alpha of 0.05 our study demonstrated 95% power.  
Discussion 
This is the largest to date cohort of MINOCA patients assessed with CMR, and the first study to 
assess the prognostic role of CMR and conventional risk factors in patients with MINOCA. The 
main findings are as follows: 1) CMR can identify a diagnosis in 3/4 patients presenting with 
MINOCA and suitable for CMR assessment, 2) CMR diagnosis of cardiomyopathy (imaging) 
and ECG presentation with ST-elevation (conventional risk marker) were the strongest predictors 
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of mortality, 3) a combined risk assessment tool using the 2 parameters (cardiomyopathy and 
ECG presentation with ST-elevation) provides further risk stratification in these patients.  
Diagnostic role of CMR in MINOCA 
It is important to identify a cause for MINOCA in order to guide ongoing management and 
provide patient’s guidance. As a non-invasive imaging technique, CMR (done at median of 
37days from presentation) is able to identify a diagnosis in these patients in up to 3/4 cases. The 
diagnostic role of CMR in this patient group has been demonstrated in a small number of 
previous studies with smaller sample sizes. (11–17) However, the diagnostic yield of CMR in the 
literature was disparate, ranging from as low as 30% to as high as 90%. (11–17)  The variation in 
the diagnostic yield in the literature can be explained by the use of incomplete CMR protocol 
(oedema imaging not always included) as well as the timing of the test, sometimes occurring 
several months after the acute event leading to the resolution of the reversible cardiac 
abnormalities. (13,18) 
In our cohort, the most common diagnosis was MI (25%, n=97), closely followed by myocarditis 
(25%, n=96) and cardiomyopathy (25%). However, the literature suggests myocarditis to be 
much more common than MI (10-13, 15), contrary to our result. The mean age in our study was 
much higher compared to the other studies on MINOCA which may have contributed to the 
higher prevalence of MI.(14,15) Another possible explanation could be the use of established 
criteria (Lake Louise Criteria) for diagnosing myocarditis(26), as well as an inclusion cut-off of 
<50% coronary artery stenosis.(10-15)  
Prognostic role of CMR in MINOCA  
Of all the CMR parameters examined (including LV size, LV function, LV mass, myocardial 
oedema, LGE and the overall CMR diagnosis), a CMR diagnosis of cardiomyopathy was 
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associated with the worst prognosis (15% mortality). On a multivariable analysis involving both 
traditional markers and CMR characteristics, CMR-derived diagnosis of cardiomyopathy 
remained significant as an independent predictor of mortality.   
Among the other CMR parameters assessed, LV ejection fraction and LV indexed end-diastolic 
volume were significant univariable predictors of mortality but not in multivariable analysis. 
These findings are particularly useful in justifying the role of CMR tissue characterization in 
MINOCA.  
The cardiomyopathy group in our study was a heterogenous group with Takotsubo 
cardiomyopathy being the most common (43% of the cardiomyopathy group). Takotsubo 
cardiomyopathy had the worst prognosis over a median follow up of 3.5 years (15% overall 
mortality) when compared to any other CMR diagnosis. The findings are comparable to the 
recent study by Templin et al. in which Takotsubo cardiomyopathy had a mortality of 5.6% per 
patient-year in long term follow up.(21) CMR not only helps in diagnosis but it may also help in 
identifying the high risk Takotsubo cardiomyopathy cases by delineating the amount of 
myocardial oedema, RV involvement, thrombus, LV outflow tract obstruction. CMR derived 
apico-basal myocardial oedema gradient may be used as a marker of malignant arrhythmia 
risk.(28)  
Conventional risk factors for prognosis assessment 
Out of all the risk factors assessed, ECG presentation with ST-elevation was an independent 
predictor of mortality. Age and log peak troponin were univariable predictors of mortality but 
not in multivariable analysis. Gender was not associated with mortality. The finding on peak 
troponin is particularly important as it is in contrary to the regular practice.  High peak troponin 
level is often used as an arbitrary prognostic marker due to its evidence from acute coronary 
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syndrome trials. (29) The importance of the presentation ECG is a novel finding as it is often 
overlooked while managing patients with MINOCA. 
Clinical implication 
Our findings strengthen the evidence that CMR is a clinically relevant non-invasive imaging 
modality for the assessment of patients presenting with MINOCA. In a previous study we have 
demonstrated that CMR in MINOCA leads to a change in diagnosis in 54% and change in 
management in 41%. (18) The current study reinforces the impact of CMR, as a diagnosis of 
cardiomyopathy is associated with worst prognosis. Any other diagnosis except cardiomyopathy 
had a relatively low mortality (2-4%) thereby putting them in a good prognostic category.  
Currently, there is no risk stratification algorithm for patients presenting with MINOCA. The 
results of our study suggest that ECG at presentation and CMR diagnosis might be useful 
predictors for risk stratification. This should be explored further and confirmed in larger 
multicenter studies.  
Limitations 
Several limitations merit consideration. This is a single centre study with relatively limited 
sample size. Although our study was designed to represent a real-world population, we 
potentially might have excluded higher-risk patients with contraindications to CMR (e.g., 
creatinine clearance <30 ml/min and intracardiac devices). However, our study included a broad 
range of consecutive MINOCA patients from a large catchment area, and only a limited number 
(2%) of patients were excluded from CMR. There may have been a referral bias as the study 
included MINOCA patients, referred for a CMR by the physician providing the care. However, 
our regular clinical practice at the Bristol Heart Institute includes CMR in patients presenting 
with MINOCA. The CMR was performed at a median of 37 days from presentation and this may 
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have impacted the diagnostic pick up rate as well as the prevalence of myocardial oedema, as not 
all patients were imaged in the acute phase. Nevertheless, our study showed a significant 
prognostic impact irrespective of the timing of scan. Also, newer mapping techniques were not 
performed in this patients’ cohort.  The normal CMR group had few patients with bundle branch 
block and LGE in the insertion points which may not be classed as entirely normal, however the 
presence of diffuse myocardial injury was excluded on the basis of both the early gadolinium 
enhancement and T2 weighted images analysis. Lastly, myocardial biopsy was not carried out in 
these patients. However, well-established and clinically validated CMR criteria were used for the 
diagnosis of the individual cases.  
Conclusion 
In a large cohort of MINOCA, CMR (median 37days from presentation) established a diagnosis 
in almost 3/4 of cases. Among the conventional risk factors and CMR characteristics, ST-
segment elevation on presentation ECG and CMR diagnosis of cardiomyopathy were 
independent predictors of mortality. Combined analysis of CMR diagnosis and ECG at 
presentation may allow stratification of patients with poor outcomes. 
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PERSPECTIVES 
COMPETENCY IN MEDICAL KNOWLEDGE: 
CMR (median 37days from presentation) enabled in establishing a diagnosis in 74% of patients 
presenting with MINOCA. Patients presenting with ST-elevation on ECG and CMR diagnosis of 
cardiomyopathy have worse prognosis. 
 
TRANSLATIONAL OUTLOOK: 
x Clinical relevance: MINOCA is common and often represent a clinical dilemma 
x Current ESC/ACC guidelines suggest some diagnostic tests but there is no recommended 
work up and management of MINOCA 
x CMR is useful for both diagnosis and prognostication in MINOCA 
x Large multicentre prospective trial is warranted to confirm these results and thereby 
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Figure legends:  
 
Figure 1. Study flow-chart 
 
Figure 2. Age as a marker of mortality.  
Kaplan-Meier curves showing the risk of mortality according to age group. 
 
Figure 3. ECG at presentation.  
Kaplan-Meier curves showing the risk of mortality according to presence or absence of ST 
segment elevation on the presenting ECG 
 
Figure 4.  Cumulative Mortality According to CMR diagnosis.  
4a: Kaplan-Meier curves showing the risk of mortality according to CMR diagnosis (MI vs 
Myocarditis vs Cardiomyopathy vs normal), 4b: Kaplan-Meier curves showing the risk of 
mortality according to CMR diagnosis of Takotsubo cardiomyopathy vs any other diagnosis  
 
Figure 5: Prognostic role of CMR diagnosis and ECG in MINOCA.  
(Left) In a population of patients presenting with MINOCA, CMR identified 4 main categories – 
Cardiomyopathy (Takotsubo), Myocarditis, Myocardial infarction and normal, Right: Kaplan-
Meier curves showing the risk of mortality according to risk group (Group A - Any CMR 
diagnosis except cardiomyopathy & presentation as NSTE-ACS, Group B - CMR diagnosis of 
cardiomyopathy or presentation as STEMI, Group C - CMR diagnosis of cardiomyopathy & 
presentation as STEMI) 
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Table 1. Demographic characteristics.  
Characteristics 




n=388 n=97 n=96 n=96 n=99 p-value 
Mean age in yrs (SD) 56 (17) 62(12) 42(17) 64(12) 54(16) <0.001 
Female sex % 48 56 23 61 54 <0.001 
Family history of 
IHD % 
3 2 4 1 3 0.57 
Diabetes % 6 8 5 6 4 0.64 
Hypertension % 13 16 9 14 14 0.54 
History of smoking 
% 
7 4 5 10 7 0.32 
BMI 26.5 27.3 26.5 25.7 26.4 0.18 
Troponin T ng/L 
median 
497 660 924 419 202 0.03 
Presentation as 
STEMI % 
19 19 19 25 14 0.29 
Median interval in 
days (presentation 
and CMR) 
37 37 21 12 47 <0.001 
Median Follow up  
(days) 
1262 1246 1336 1231 1276 0.09 
 23 
All cause mortality 
%(n) 
6 (22) 4 (4) 2 (2) 15 (14) 2 (2) <0.001 
 
 
MI- myocardial infarction, IHD – ischaemic heart disease, BMI – body mass index, STEMI- ST 
elevation myocardial infarction, CMR- cardiac magnetic resonance. 
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Table 2. CMR characteristics of the different diagnostic categories 
CMR 
Characteristics 
Total MI Myocarditis Cardiomyopathy Normal Global  
n=388 n=97 n=96 n=96 n=99 p-value 
iEDV ml/m2 81 78 83 90 74 <0.001 
iESV ml/m2 34 30 32 47 26 <0.001 
iSV ml/m2 47 48 50 43 48 <0.001 
LVEF % 61 63 62 52 67 <0.001 
iLV  mass gm/m2 66 63 67 75 59 <0.001 
RWMA % 39 59 31 59 6 <0.001 
LGE % 58 100 94 34 6 <0.001 
No. of LGE 
segments(IQR) 
1(0-2) 1(1-2) 3(2-4) 0(0-1) 0 <0.01 
Myocardial 
oedema % 
34 52 52 34 0 <0.001 
No. of Oedema 
segments(IQR) 
0(0-2) 1(0-2) 2(0-4) 0(0-5) 0 <0.01 
iEDV-  indexed end-diastolic volume, iESV =-indexed end-systolic volume, iSV- indexed 
stroke volume; LVEF- left ventricular ejection fraction, iLV- indexed left ventricular, 
RWMA- regional wall motion abnormality, LGE – late gadolinium enhancement 
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TCM DCM HCM Others Global 
n=41 n=28 n=17 n=10 p-value 
Mean age (SD) 68(10) 63(13) 60(17) 60(12) 0.05 
Female sex % 98 32 47 33 <0.001 
STEMI % 38 18 24 0 0.07 
iEDV ml/m2 77 128 67 81 <0.001 
iESV ml/m2 35 87 20 36 <0.001 
iSV ml/m2 42 41 48 44 0.298 
LVEF % 56 33 70 59 <0.001 
iLV  mass gm/m2 61 85 87 88 <0.001 
Mortality(n) 6 5 0 3 <0.01 
 
TMC- Tako Tsubo cardiomyopathy, DCM- dilated cardiomyopathy, HCM -hypertrophic 
cardiomyopathy, iEDV-  indexed end-diastolic volume, iESV -indexed end-systolic volume, 




Table 4. Treatment prior to CMR 
Pre-CMR 
Treatment 
MI Myocarditis Cardiomyopathy Normal Global  
n=97 n=96 n=96 n=99 p-value 
Aspirin 95 92 91 92 0.81 
Other 
Antiplatelet 
61 59 60 63 0.31 
ACE-inhibitor/ 
ARB 
65 66 69 66 0.92 
Beta-blocker 65 64 71 62 0.58 
Statin 62 53 59 56 0.66 
 
CMR- cardiac magnetic resonance, MI- myocardial infarction, ARB- angiotensin receptor 
blockers 
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Table 5. Univariable and multivariable association for mortality 
  Univariate analysis Multivariate analysis 
Variables          Sig.      HR 
                 95% CI 
         Sig.      HR 
                95% CI 
   Lower    Upper    Lower    Upper 
Age group 0.008 2.046 1.203 3.48 0.1 1.645 0.908 2.978 
Sex 0.302 1.564 0.669 3.659 - - - - 
BMI 0.484 0.968 0.884 1.06 - - - - 
Log-Peak 
Troponin  
0.041 0.509 0.267 0.971 0.094 0.565 0.29 1.101 
STEMI 0.01 3.059 1.307 7.157 0.013 3.125 1.271 7.684 
iEDV 0.008 1.016 1.004 1.028 0.258 1.01 0.993 1.028 
LVEF 0.001 0.958 0.936 0.981 0.851 .996 0.96 1.034 
RWMA 0.132 1.905 0.823 4.41 - - - - 
LGE 0.161 0.544 0.233 1.274 - - - - 
Oedema 0.228 0.542 0.2 1.469 - - - - 
MI 0.472 0.672 0.227 1.986 - - - - 
Myocarditis 0.098 0.293 0.068 1.253 - - - - 
CM 0.001 5.628 2.361 13.417 0.034 3.013 1.084 8.373 
Normal  0.091 0.285 0.067  1.219 - - - - 
 
BMI – Body mass index, STEMI- ST elevation myocardial infarction, LVEF – left ventricular 
ejection fraction, iEDV – indexed end diastolic volume, RWMA- regional wall motion 
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abnormality, LGE – late gadolinium enhancement, MI – myocardial infarction, CM - 
cardiomyopathy 





